This can be achieved by utilising a biomarker enrichment strategy—in which biomarkers are applied to select a particular study population for initial therapy (e.g., high PD-L1 expressing NSCLC, recruited to receive ICI monotherapy)—followed by customisation of the therapeutic approach as guided by disease response or lack thereof. This evidence concerns the gene CD274 and non-small cell lung carcinoma.